Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
341actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-23 | actual | When the study began enrolling |
| Primary completion | 2025-03-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-28 | actual | The whole study's end, after follow-up |
| First posted | 2026-07-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed/Refractory Multiple Myeloma
Interventions
- Drug: Pomalidomide-containing regimens
- Drug: Non-pomalidomide-containing regimens
Primary outcomes
what the primary-completion date above is the date OFProgression-Free Survival (PFS) among participants who initiated pomalidomide-containing index regimens
measured Up to 6 years
Overall Survival (OS) among participants who initiated pomalidomide-containing index regimens
measured Up to 6 years
Overall Response Rate (ORR) among participants who initiated pomalidomide-containing index regimens
measured Up to 6 years
Time to Next Treatment (TTNT) among participants who initiated pomalidomide-containing index regimens
measured Up to 6 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed